Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis

February 2024 | Volume 23 | Issue 2 | 23 | Copyright © February 2024


Published online January 18, 2024

Lawrence F. Eichenfield MDa,b, Jonathan I. Silverberg MD PhD MPHc, Adelaide A. Hebert MDd, Raj Chovatiya MD PhDe, Philip M. Brown MD JDf, Kimberly A. McHale PhDf, David S. Rubenstein MD PhDf, Anna M. Tallman PharmDf

aUniversity of California San Diego School of Medicine, San Diego, CA
bRady Children’s Hospital, San Diego, CA
cSchool of Medicine and Health Sciences, The George Washington University, Washington, DC
dUTHealth McGovern Medical School and Children’s Memorial Hermann Hospital, Houston, TX
eNorthwestern University Feinberg School of Medicine, Chicago, IL
fDermavant Sciences, Inc., Morrisville, NC

  1. Hidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017;18(1):64-73. 
  2. Haarmann-Stemmann T, Esser C, Krutmann J. The Janus-faced role of AhR signaling in the skin: consequences for prevention and treatment of skin disorders. J Invest Dermatol. 2015;135(11):2572-2576. 
  3. Baek J-O, Cho J, Roh J-Y. Associations between ambient air pollution and medical care visits for atopic dermatitis. Environ Res. 2021;195:110153. 
  4. Wang H, Sun J, Qian Z, et al. Association between air pollution and atopic dermatitis in Guangzhou, China: modification by age and season. Br J Dermatol. 2021;184(6):1068-1076. 
  5. Khazaal AQ, Haque N, Krager CR, et al. Aryl hydrocarbon receptor affects circadian-regulated lipolysis through an E-Box-dependent mechanism. Mol Cell Endocrinol. 2023;559:111809. 
  6. Yoshimatsu Y, Sujino T, Miyamoto K, et al. Aryl hydrocarbon receptor signals in epithelial cells govern the recruitment and location of Helios+ Tregs in the gut. Cell Rep. 2022;39(6):110773. 
  7. Han SG, Han S-S, Toborek M, Hennig B. EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes. Toxicol Appl Pharmacol. 2012;261(2):181- 188. 
  8. Niestroy J, Barbara A, Herbst K, et al. Single and concerted effects of benzo [a] pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol In Vitro. 2011;25(3):671-683. 
  9. Tsuji G, Takahara M, Uchi H, et al. Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes. J Invest Dermatol. 2012;132(1):59-68. 
  10. Fernández-Gallego N, Sánchez-Madrid F, Cibrian D. Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cells. 2021;10(11):3176. 
  11. Haas K, Weighardt H, Deenen R, et al. Aryl hydrocarbon receptor in keratinocytes is essential for murine skin barrier integrity. J Invest Dermatol. 2016;136(11):2260-2269. 
  12. Esser C, Bargen I, Weighardt H, et al. Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol. 2013;35(6):677-691. 
  13. Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424. 
  14. Riaz F, Pan F, Wei P. Aryl hydrocarbon receptor: The master regulator of immune responses in allergic diseases. Front Immunol. 2022;13:1057555. 
  15. Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21(15):5382. 
  16. Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013;65(4):1148-1161. 
  17. Li S, Bostick JW, Zhou L. Regulation of innate lymphoid cells by AhR. Front Immunol. 2018;8:1909. 
  18. Sutter CH, Olesen KM, Bhuju J, et al. AHR regulates metabolic reprogramming to promote SIRT1-dependent keratinocyte differentiation. J Invest Dermatol. 2019;139(4):818-826. 
  19. Furue M, Uchi H, Mitoma C, et al. Antioxidants for healthy skin: the emerging role of AhR and nuclear factor-erythroid 2-related factor-2. Nutrients. 2017;9(3):223. 
  20. Furue M, Ulzii D, Vu Y, et al. Pathogenesis of atopic dermatitis: Current paradigm. Iran J Immunol. 2019;16(2):97-107. 
  21. Yao Y, Ravn Jørgensen A-H, Thomsen SF. Biologics for chronic inflammatory skin diseases: an update for the clinician. J Dermatolog Treat. 2020;31(2):108- 130. 
  22. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America study. J Invest Dermatol. 2019;139(3):583-590. 
  23. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476-486. 
  24. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. 
  25. Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. StatPearls. Treasure Island (FL); StatPearls Publishing; 2023. 
  26. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135-140. 
  27. Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):21-31. 
  28. Løset M, Brown SJ, Saunes M, Hveem K. Genetics of atopic dermatitis. Dermatology. 2019;235(5):355-364. 
  29. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446. 
  30. Irvine AD, McLean WI, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-1327. 
  31. Ji H, Li X-K. Oxidative stress in atopic dermatitis. Oxid Med Cell Longev. 2016;2016:2721469. 
  32. Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. 
  33. Kim J, Han Y, Ahn J, et al. Airborne formaldehyde causes skin barrier dysfunction in atopic dermatitis. Br J Dermatol. 2016;175(2):357-363. 
  34. Wang C, Wei C-C, Wan L, et al. Association of exposure to hydrocarbon air pollution with the incidence of atopic dermatitis in children. Ital J Pediatr. 2021;47:1-9. 
  35. Nakajima S, Tie D, Nomura T, Kabashima K. Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans. Cytokine. 2021;148:155664. 
  36. Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the treatment of atopic dermatitis. Immunotargets Ther. 2020:151-156. 
  37. Yamanaka K-i, Mizutani H. The role of cytokines/chemokines in the pathogenesis of atopic dermatitis. Curr Probl Dermatol. 2011;41:80-92. 
  38. Zhang Y, Jing D, Cheng J, et al. The efficacy and safety of IL-13 inhibitors in atopic dermatitis. Front Immunol. 2022;13:923362. 
  39. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. 
  40. Strober B, Gold LS, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800-806. 
  41. Mooney N, Teague J, Gehad A, et al. Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in vitro. Society For Investigative Dermatology, May 18–21, 2022. 
  42. Zaid A, Mackay LK, Rahimpour A, et al. Persistence of skin-resident memory T cells within an epidermal niche. Proc Natl Acad Sci. 2014;111(14):5307- 5312. 
  43. Stein Gold L, Lebwohl MG, Brown PM, et al. Tapinarof cream 1% once daily for plaque psoriasis in two pivotal phase 3 trials: Minimal systemic exposure is consistent with adverse event profile. American Academy of Dermatology Conference, March 17-21, 2023. 
  44. Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83-91. 
  45. Paller A, Jett JE, Hebert AA, et al. Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial. Annual Revolutionizing Atopic Dermatitis Conference, April 29-May 1, 2023. 
  46. Dermavant Sciences. Press Release. May 16, 2023. Available at: https:// tinyurl.com/hx46twey. Accessed August 11, 2023. 

AUTHOR CORRESPONDENCE

Lawrence F. Eichenfield MD leichenfield@rchsd.org
Close Menu